RxDoctor Payments Data

Matthew Friend, DO

Family Medicine · Columbus, OHNPI 1538628300

Payments from drug & device makers

$1,057in general payments, 2019–2025

Across 53 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$251
  • Lilly USA, LLC$233
  • Astellas Pharma US Inc$99
  • Novo Nordisk$88
  • Bayer$76
  • GSK$67
  • plus $243 from 8 others

What the payments were for

  • Food & beverage$95891%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,057 in reported general payments places this provider in the 60th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$29,982
Medicare patients
103
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$74,123
JardianceEmpagliflozin45$68,593
JanuviaSitagliptin Phosphate26$35,714
TrulicityDulaglutide16$32,535
EliquisApixaban21$26,871
MounjaroTirzepatide19$24,728
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$20,666
FarxigaDapagliflozin Propanediol13$15,235
XareltoRivaroxaban11$11,447
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$7,471
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$5,254
Arnuity ElliptaFluticasone Furoate20$4,809
Atorvastatin Calcium370$3,585
Gabapentin153$2,898
Albuterol Sulfate HfaAlbuterol Sulfate92$2,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$88$74,12350 claims
Lilly USA, LLCTrulicity, Mounjaro$233$57,26335 claims
PfizerEliquis$36$26,87121 claims
GSKTrelegy Ellipta, Arnuity Ellipta$67$25,47644 claims
AstraZenecaFarxiga$43$15,23513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →